Nuvios is a leader in the discovery and development of a new generation of drug therapies for treating and preventing osteoporosis and metabolic bone diseases. The company’s primary focus is on discoveries related to the growth of osteoblasts and osteoclasts, which enable the formation of bone with high specificity. Nuvios’ scientific leadership includes some of the world’s leading researchers in the fields of bone metabolism and medicinal chemistry.